NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Vertex Pharmaceuticals Inc. / MA VRTX
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$12.0B
▲ 8.9% vs FY2024
EPS · FY25
$15.32
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
22.5%
Net margin · FY25
32.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 12.0B
Revenue, FY2025 · full 18-year series below
Revenue
Net income
33 cents of every revenue dollar became profit this year.
Per share
USD 15.32
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
22.5%
Return on equity, FY2025
ROE
Operating margin34.8%
Net margin32.9%
Return on assets16.4%
Each USD of equity produced 23 cents of profit this year.
Returned to shareholders
USD 2.0B
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 2.0B
Share of profit49.6%
Consecutive raises—
USD 2.0B in buybacks — 50% of the year's profit went back to shareholders.
Growth
+14.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+10.4%
+14.1%
+27.8%
+34.3%
Net income
+6.0%
+7.8%
EPS, diluted
+6.1%
+8.3%
Returned to shareholders
+44.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.25B
Shares outstanding, FY2025
Change, 5 years−2.3%
Change, 10 years+3.1%
The share count shrank 2% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 25.6B
total assets, end of FY2025
Total assetsUSD 25.6B
EquityUSD 18.7B
CashUSD 5.1B
Current ratio2.90×
Equity funds 73% of total assets.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
12.0
11.0
9.9
8.9
7.6
6.2
4.2
3.0
2.5
1.7
1.0
0.6
1.2
1.5
1.4
0.1
0.1
0.2
Operating income $B
4.2
−0.2
3.8
4.3
2.8
2.9
1.2
0.6
0.1
0.0
−0.5
−0.7
−0.6
0.0
0.1
−0.7
−0.6
−0.5
EBITDA $B
4.4
−0.0
4.0
4.5
2.9
3.0
1.3
0.7
0.2
0.1
−0.4
−0.6
−0.6
0.1
0.1
−0.7
−0.6
−0.4
Income tax $B
0.7
0.8
0.8
0.9
0.4
0.4
0.2
−1.5
−0.1
0.0
0.0
0.0
−0.1
−0.0
0.0
0.0
·
·
Net income $B
4.0
−0.5
3.6
3.3
2.3
2.7
1.2
2.1
0.3
−0.1
−0.6
−0.7
−0.4
−0.1
0.0
−0.8
−0.6
−0.5
EPS, diluted $
15.32
−2.08
13.89
12.82
9.01
10.29
4.51
8.09
1.04
−0.46
−2.31
−3.14
−1.98
−0.50
0.14
−3.77
−3.71
−3.27
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
22.5
−3.2
23.0
27.7
24.9
36.7
22.4
64.9
16.5
−10.7
−55.2
−60.8
−37.8
−12.0
4.6
−149.7
·
·
Shares out B
0.25
0.26
0.26
0.26
0.25
0.26
0.26
0.26
0.25
0.25
0.25
0.24
0.23
0.22
0.21
0.20
0.20
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
52 of 52
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed